Retatrutide, tested at 9 mg and 12 mg doses alongside diet and exercise, met all primary and key secondary endpoints
This partnership strengthens LMS as a leading CDMO supplier of peptide materials for both innovator and generic markets
The company has unveiled the results of pirtobrutinib from its BRUIN CLL-313 study
The new site will produce next-generation synthetic medicine active pharmaceutical ingredients
HYMPAVZI’s safety profile was generally favorable
Takeda will pay Innovent US$1.2 billion upfront, including a US$100 million equity investment in Innovent
Biocon will acquire the residual stake held by Mylan (Viatris) for a total consideration of US$ 815 million
Valorum will advance the commercialization and distribution of Armlupeg in the United States
Siponimod Tablets is indicated for the treatment of relapsing forms of multiple sclerosis
Roche says the move marks a step forward in its digital transformation strategy
Subscribe To Our Newsletter & Stay Updated
